Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromuscular Diseases | 2 | 2022 | 65 | 1.350 |
Why?
|
| Diabetic Neuropathies | 7 | 2021 | 92 | 1.250 |
Why?
|
| Neural Conduction | 3 | 2020 | 109 | 0.770 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2020 | 4 | 0.720 |
Why?
|
| Patient Preference | 1 | 2022 | 229 | 0.680 |
Why?
|
| Placebo Effect | 2 | 2017 | 37 | 0.600 |
Why?
|
| Neuralgia | 2 | 2021 | 265 | 0.590 |
Why?
|
| Myositis, Inclusion Body | 3 | 2023 | 8 | 0.590 |
Why?
|
| Drinking | 1 | 2017 | 52 | 0.560 |
Why?
|
| Distal Myopathies | 1 | 2016 | 1 | 0.560 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2017 | 106 | 0.510 |
Why?
|
| Deglutition | 1 | 2017 | 187 | 0.510 |
Why?
|
| Telemedicine | 1 | 2022 | 553 | 0.500 |
Why?
|
| Genetic Testing | 1 | 2022 | 1695 | 0.450 |
Why?
|
| Receptors, Virus | 1 | 2014 | 153 | 0.450 |
Why?
|
| Retinitis Pigmentosa | 1 | 2014 | 83 | 0.440 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 246 | 0.420 |
Why?
|
| Ataxia | 1 | 2014 | 183 | 0.420 |
Why?
|
| Quinidine | 1 | 2012 | 13 | 0.410 |
Why?
|
| Dextromethorphan | 1 | 2012 | 15 | 0.410 |
Why?
|
| Acetamides | 2 | 2009 | 111 | 0.380 |
Why?
|
| Fatigue | 1 | 2017 | 1278 | 0.360 |
Why?
|
| Ribonucleotide Reductases | 1 | 2009 | 48 | 0.340 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 2009 | 28 | 0.330 |
Why?
|
| DNA Mutational Analysis | 4 | 2014 | 2357 | 0.330 |
Why?
|
| Gastrointestinal Motility | 1 | 2009 | 87 | 0.320 |
Why?
|
| Thymectomy | 2 | 2020 | 80 | 0.310 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2009 | 131 | 0.300 |
Why?
|
| DNA, Mitochondrial | 1 | 2009 | 313 | 0.290 |
Why?
|
| Double-Blind Method | 9 | 2023 | 2584 | 0.290 |
Why?
|
| Myasthenia Gravis | 2 | 2020 | 106 | 0.290 |
Why?
|
| Prednisone | 2 | 2020 | 1031 | 0.250 |
Why?
|
| Gastrointestinal Diseases | 2 | 2009 | 604 | 0.250 |
Why?
|
| Pain | 2 | 2009 | 1699 | 0.220 |
Why?
|
| Dystrophin | 1 | 2021 | 48 | 0.190 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2021 | 121 | 0.180 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2021 | 70 | 0.180 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 2117 | 0.180 |
Why?
|
| Muscle Contraction | 1 | 2021 | 229 | 0.180 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 156 | 0.180 |
Why?
|
| Muscle, Skeletal | 3 | 2021 | 1289 | 0.180 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 2 | 2010 | 19 | 0.170 |
Why?
|
| Lipid Metabolism, Inborn Errors | 2 | 2010 | 19 | 0.170 |
Why?
|
| Plasmids | 1 | 2021 | 936 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3398 | 0.160 |
Why?
|
| Humans | 24 | 2023 | 270457 | 0.150 |
Why?
|
| Adult | 13 | 2023 | 81754 | 0.140 |
Why?
|
| Male | 18 | 2023 | 128105 | 0.140 |
Why?
|
| Myoclonus | 1 | 1997 | 35 | 0.140 |
Why?
|
| Middle Aged | 14 | 2021 | 90100 | 0.140 |
Why?
|
| Mutation | 3 | 2014 | 15908 | 0.140 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2017 | 60 | 0.140 |
Why?
|
| Placebos | 2 | 2021 | 443 | 0.140 |
Why?
|
| Communication | 1 | 2022 | 856 | 0.130 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 1997 | 200 | 0.130 |
Why?
|
| Polyneuropathies | 1 | 2015 | 28 | 0.130 |
Why?
|
| Spiro Compounds | 1 | 2015 | 59 | 0.130 |
Why?
|
| Female | 19 | 2023 | 148644 | 0.130 |
Why?
|
| Pain Measurement | 4 | 2021 | 1017 | 0.120 |
Why?
|
| Treatment Outcome | 9 | 2021 | 33708 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1430 | 0.110 |
Why?
|
| Heart Rate | 1 | 2017 | 755 | 0.110 |
Why?
|
| Action Potentials | 1 | 2017 | 598 | 0.110 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1997 | 409 | 0.110 |
Why?
|
| Psychometrics | 1 | 2018 | 969 | 0.110 |
Why?
|
| Genetic Therapy | 1 | 2021 | 1714 | 0.110 |
Why?
|
| Family Health | 1 | 2014 | 349 | 0.110 |
Why?
|
| Aged | 10 | 2021 | 73175 | 0.110 |
Why?
|
| Pyrazines | 1 | 2015 | 511 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2016 | 619 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2017 | 1158 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2017 | 574 | 0.100 |
Why?
|
| Muscle Weakness | 1 | 2012 | 111 | 0.090 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2012 | 101 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 163 | 0.090 |
Why?
|
| Muscular Atrophy | 1 | 2012 | 107 | 0.090 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2012 | 199 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 4364 | 0.090 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 50 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2012 | 635 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 5921 | 0.080 |
Why?
|
| Cataract | 1 | 2012 | 236 | 0.080 |
Why?
|
| Basal Ganglia | 1 | 2009 | 62 | 0.080 |
Why?
|
| RNA, Transfer | 1 | 2009 | 88 | 0.080 |
Why?
|
| Neurologic Examination | 1 | 2009 | 263 | 0.080 |
Why?
|
| Ovary | 1 | 2012 | 688 | 0.080 |
Why?
|
| Quality of Life | 3 | 2018 | 4773 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2020 | 416 | 0.070 |
Why?
|
| Biopsy | 2 | 2009 | 3387 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 983 | 0.070 |
Why?
|
| Analgesics | 2 | 2007 | 409 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2006 | 56 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 559 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 3471 | 0.050 |
Why?
|
| Animals | 4 | 2023 | 62021 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 1689 | 0.050 |
Why?
|
| Isometric Contraction | 1 | 2021 | 20 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 30936 | 0.050 |
Why?
|
| Walk Test | 1 | 2021 | 43 | 0.050 |
Why?
|
| Time | 1 | 2021 | 183 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 247 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2021 | 104 | 0.040 |
Why?
|
| Carnitine | 2 | 2010 | 88 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 142 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2017 | 12104 | 0.040 |
Why?
|
| Disease Progression | 2 | 2023 | 6842 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 256 | 0.040 |
Why?
|
| Young Adult | 5 | 2020 | 22152 | 0.040 |
Why?
|
| Sural Nerve | 1 | 1997 | 60 | 0.040 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1997 | 134 | 0.040 |
Why?
|
| Toes | 1 | 1997 | 48 | 0.040 |
Why?
|
| Pressure | 1 | 1997 | 189 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 440 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 2854 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 9041 | 0.030 |
Why?
|
| Thymoma | 1 | 2020 | 252 | 0.030 |
Why?
|
| Brain | 1 | 2009 | 4209 | 0.030 |
Why?
|
| Time Factors | 1 | 2009 | 12991 | 0.030 |
Why?
|
| Thymus Neoplasms | 1 | 2020 | 416 | 0.030 |
Why?
|
| United States | 2 | 2023 | 15856 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 4222 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 7897 | 0.030 |
Why?
|
| DNA Polymerase gamma | 1 | 2012 | 15 | 0.030 |
Why?
|
| Glutarates | 1 | 2012 | 41 | 0.030 |
Why?
|
| Ovarian Diseases | 1 | 2012 | 51 | 0.020 |
Why?
|
| Rats | 1 | 2020 | 6522 | 0.020 |
Why?
|
| Term Birth | 1 | 2010 | 34 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 852 | 0.020 |
Why?
|
| Succinate Dehydrogenase | 1 | 2009 | 49 | 0.020 |
Why?
|
| DNA | 1 | 1997 | 3049 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 2009 | 145 | 0.020 |
Why?
|
| Triazines | 1 | 2009 | 122 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 7371 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6188 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 32671 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2010 | 348 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 2163 | 0.020 |
Why?
|
| Dizziness | 1 | 2006 | 43 | 0.020 |
Why?
|
| Headache | 1 | 2007 | 175 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2007 | 271 | 0.010 |
Why?
|
| Nausea | 1 | 2006 | 540 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2006 | 443 | 0.010 |
Why?
|
| Mice | 1 | 2023 | 35592 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2006 | 676 | 0.010 |
Why?
|
| Heart | 1 | 2007 | 1195 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 5071 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 8101 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8626 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2018 | 39751 | 0.010 |
Why?
|